Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
Earnings Data
Report Date
May 21, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.84Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -13.11%
|Next Earnings Date:May 21, 2025
Earnings Call Sentiment|Positive
The earnings call highlights BioLineRx's transformational licensing agreement and significant revenue growth, indicating a positive outlook with a strong financial position and promising clinical developments. However, the shutdown of U.S. operations and challenges in PDAC development highlight ongoing strategic adjustments.Company Guidance
During the BioLineRx Fourth Quarter and Full Year 2024 Financial Results Conference Call, CEO Phil Serlin highlighted key metrics reflecting the company's strategic shift and financial performance. BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and making the company eligible for $87 million in potential milestones and sales royalties ranging from 18% to 23%. The company reported total revenues of $28.9 million for 2024, a 502.1% increase from 2023. The shutdown of U.S. operations and headcount reduction in Israel reduced annual operating cash burn by 70%, from over $40 million to approximately $12 million. Additionally, BioLineRx ended the year with pro forma cash of $29 million and a cash runway projected to fund operations through the second half of 2026. The company is focused on expanding its pipeline by evaluating early clinical stage and late pre-clinical stage therapeutic assets in oncology and rare diseases, leveraging its drug development expertise.Transformational Licensing Agreement with Ayrmid Pharma
BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and eligibility for $87 million in potential milestones, along with 18% to 23% sales royalties.
Significant Revenue Growth
Total revenues for 2024 were $28.9 million, a 502.1% increase from $4.8 million in 2023, driven by upfront payments and milestones from licensing agreements.
Operational Streamlining and Cost Reduction
BioLineRx reduced operating cash burn by approximately 70%, from over $40 million annually to about $12 million, following the shutdown of U.S. operations and headcount reduction in Israel.
Strong Financial Position
BioLineRx ended 2024 with $29 million in pro forma cash and a cash runway projected to fund operations through the second half of 2026.
Promising Clinical Developments in Sickle Cell Disease
Positive initial results from motixafortide trials in sickle cell disease, showing the potential to mobilize enough stem cells for gene therapies in fewer cycles.
---
BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $3.05 | $2.96 | -2.95% |
| Nov 25, 2024 | $11.12 | $10.87 | -2.25% |
| Aug 15, 2024 | $31.00 | $27.13 | -12.48% |
| May 28, 2024 | $27.40 | $28.76 | +4.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?
Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on May 21, 2025, TBA Not Confirmed.
What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?
Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at May 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLRX EPS forecast?
BLRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.84.
---